- Home
- MDXH vs NVCT Comparison
MDXH vs NVCT Comparison
Compare MDXH & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MDXH | NVCT |
|---|---|---|
| Founded | 2003 | 2020 |
| Country | Belgium | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 203.4M | 171.9M |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | MDXH | NVCT |
|---|---|---|
| Price | $3.35 | $7.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $7.67 | ★ $15.33 |
| AVG Volume (30 Days) | ★ 187.0K | 91.2K |
| Earning Date | 11-12-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $103,069,000.00 | N/A |
| Revenue This Year | $23.34 | N/A |
| Revenue Next Year | $22.98 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 21.68 | N/A |
| 52 Week Low | $1.35 | $4.44 |
| 52 Week High | $5.33 | $11.52 |
Technical Indicators
Market Signals| Indicator | MDXH | NVCT |
|---|---|---|
| Relative Strength Index (RSI) | 36.56 | 73.35 |
| Support Level | $3.31 | $6.47 |
| Resistance Level | $3.74 | $6.84 |
| Average True Range (ATR) | 0.18 | 0.40 |
| MACD | 0.01 | 0.17 |
| Stochastic Oscillator | 15.97 | 92.25 |
Price Performance
Historical ComparisonAbout MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.